Last $4.76 USD
Change Today -0.01 / -0.21%
Volume 51.7K
HBIO On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

harvard bioscience inc (HBIO) Snapshot

Open
$4.79
Previous Close
$4.77
Day High
$4.79
Day Low
$4.69
52 Week High
12/20/13 - $5.15
52 Week Low
06/25/14 - $3.68
Market Cap
152.1M
Average Volume 10 Days
525.6K
EPS TTM
$0.06
Shares Outstanding
32.0M
EX-Date
--
P/E TM
84.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for HARVARD BIOSCIENCE INC (HBIO)

Related News

No related news articles were found.

harvard bioscience inc (HBIO) Related Businessweek News

No Related Businessweek News Found

harvard bioscience inc (HBIO) Details

Harvard Bioscience, Inc. develops, manufactures, distributes, and markets scientific instruments, systems, and lab consumables used in life science research. The company offers syringe pumps and peristaltic pumps primarily under the Harvard Apparatus and KD Scientific brands, as well as component pumping modules; and lab equipment and supplies comprising pipettes and pipette tips, gloves, gel electrophoresis and autoradiography products, thermal cycler accessories and reagents, general lab equipment and consumables, and tissue culture products primarily under the Denville Scientific, Hoefer, and Scie-Plas brands. It also provides molecular analysis products, such as spectrophotometers under the UltroSpec, NovaSpec, Libra, and BioDrop brands; microplate readers under the Asys Hitech and Anthos Labtec brands; and amino acid analyzers under the Biochrom brand. In addition, the company offers electroporation and electrofusion products comprising systems and generators, electrodes, and accessories under the Harvard Apparatus BTX brand; and cell electrophysiology products, such as equipment for patch clamps, amplifiers, bilayer workstations, temperature controllers, chambers, and accessories under the Warner Instrument brand. Further, it provides physiology products, which include a range of instruments and accessories for tissue, organ, and animal based lab research, ranging from surgical products, infusion systems, microdialysis instruments, behavior research products, isolated perfused organ and tissue bath systems, and research-based regenerative medicine products under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, Hugo-Sachs, and InBreath Bioreactor brands. It markets its products to research scientists at universities, hospitals, government laboratories, and pharmaceutical and biotechnology companies through catalogs, distributors, direct sales force, and its Websites. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

345 Employees
Last Reported Date: 03/14/14
Founded in 1901

harvard bioscience inc (HBIO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $271.8K
Co-Founder and Director
Total Annual Compensation: $420.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $54.8K
Vice President of Strategic Marketing and Bus...
Total Annual Compensation: $64.5K
Vice President of Global Sales
Total Annual Compensation: $34.0K
Compensation as of Fiscal Year 2013.

harvard bioscience inc (HBIO) Key Developments

Harvard Bioscience Inc.(NasdaqGM:HBIO) dropped from Russell 2000 Index

Harvard Bioscience Inc. will be removed from the Russell 2000 Index.

Harvard Bioscience Inc.(NasdaqGM:HBIO) dropped from Russell 3000 Index

Harvard Bioscience Inc. will be removed from the Russell 3000 Index.

Harvard Bioscience Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Reiterates Financial Guidance for the Full-Year 2014

Harvard Bioscience Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. Revenues for the three months ended March 31, 2014 were $25.9 million, a decrease of approximately $0.2 million, or 0.7% compared to revenues of $26.1 million for the three months ended March 31, 2013. Overall, revenues decreased by 2.7% with currency translation having a 2.0% positive impact. Loss of work days due to winter weather in the U.S. negatively impacted revenues during the three months ended March 31, 2014. This loss of work translated to fewer consumables being used during those days. Income from continuing operations was $0.7 million, or $0.02 per diluted share, compared to $0.9 million, or $0.03 per diluted share, for the same quarter in 2013. The unfavorable year-to-year quarterly GAAP earnings comparison was due to a combination of lower gross profit, higher restructuring charges and higher interest expense, partially offset by lower transaction costs. Income from continuing operations, on a non-GAAP basis, was $1.7 million, or $0.05 per diluted share, compared to $2.1 million, or $0.07 per diluted share, for the same period in 2013. The unfavorable year-to-year quarterly non-GAAP earnings comparison was due to a combination of lower gross profit and higher interest expense. Operating income was $1,334,000 compared to $1,325,000 a year ago. Income from continuing operations before income taxes was $1,019,000 compared to $1,230,000 a year ago. Net income was $719,000 or $0.02 per diluted share compared to $96,000 or $0.00 per diluted share a year ago. Net cash provided by operating activities was $1,072,000 compared to $576,000 a year ago. Non-GAAP adjusted operating income was $2,706,000 compared to $3,133,000 a year ago. Capital expenditures were $282,000 compared to $533,000 in fourth quarter last year. The Company reiterates its financial guidance from February 27, 2014 which included revenues to be approximately the same as 2013 revenues, which were $105.2 million, and anticipates it will be a bridge year to return the Company to top-line organic growth in 2015 as it boosts its revenues and new product development. The company expects to report full-year 2014 non-GAAP income from continuing operations of $0.26 per diluted share, an improvement of approximately 20%, primarily because of operational improvements and efficiencies. This translates to GAAP income from continuing operations of $0.14 per diluted share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HBIO:US $4.76 USD -0.01

HBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $119.36 USD +0.49
Bio-Rad Laboratories Inc $117.16 USD -0.34
Danaher Corp $78.38 USD +0.38
PerkinElmer Inc $46.60 USD -0.09
Thermo Fisher Scientific Inc $118.27 USD +1.12
View Industry Companies
 

Industry Analysis

HBIO

Industry Average

Valuation HBIO Industry Range
Price/Earnings 100.0x
Price/Sales 1.4x
Price/Book 1.6x
Price/Cash Flow 113.7x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HARVARD BIOSCIENCE INC, please visit www.harvardbioscience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.